Bachem Holding AG(0QND)
GBP --+0.00%
Reward55Moderate
Risk37Moderate
75%Data
Strong 21% profit margin
0QND
+0.0 · +0.00%
GBP · LSE
Bachem Holding AG |
Balanced
Market Cap:936.11M
ⓘ
Reward Rating
55
Moderate
Reward Assessment
75% data coverage
Bottom 50% of stocksView factors
ⓘ
Risk Rating
37
Moderate
Risk Assessment
3 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on 0QND to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for 0QND, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Bachem Holding AG?

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.

0QND · Verdict

Solid reward · moderate risk

0QND stands out on cash flow and growth, but watch the profitability signal.

Based on 88% data coverage

0QND · Verdict

What’s working & what to watch

Strengths 3

  • Cash flow71/100

    -7% free-cash-flow margin

  • Growth65/100

    Rev +9.3% CAGR · earnings +13.9%

  • Volatility65/100

    Above average

Watchouts 1

  • Profitability45/100

    21% net margin · 11% ROE

Model-based scoring. For information only — not financial advice.

What is Bachem Holding AG?

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company is listed on the LSE in UK, with a market capitalisation of 936.11M, and a P/E ratio of 0.5x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Profitability metrics are mixed — margins may be under pressure.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (55)

The scoring profile indicates moderate reward potential, with growth and valuation as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
IndustryN/A
Market Cap936.11M
P/E Ratio0.4764
Dividend Yield1.16%
Beta0.795
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.